^
    5d
    SIDNEY: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Enterome | N=60 --> 80 | Trial completion date: May 2032 --> May 2034 | Trial primary completion date: May 2026 --> May 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • EO2463
    6d
    An Exploratory Clinical Study on the Safety and Efficacy of Dual Therapy Against Helicobacter pylori in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma (ChiCTR2600116306)
    P=N/A, N=45, Not yet recruiting, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University; Jiangsu Province Hospital, The First Affiliated Hospital of Na
    New trial
    6d
    Application of ⁶⁸Ga-NOTA-BCMA Nanobody PET/CT Imaging in Non-Myeloma Hematologic Malignancies (ChiCTR2500115865)
    P=N/A, N=0, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Peking Union Medical College Hospital
    New trial
    6d
    Bendamustine combined with Zuberitamab (BZ) followed by Orelabrutinib combined with Zuberitamab (OZ) in the treatment of newly diagnosed marginal zone lymphoma:A Phase II prospective clinical study (ChiCTR2500115104)
    P=N/A, N=74, Not yet recruiting, The First Affiliated Hospital of the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib) • bendamustine • Anruixi (zuberitamab)
    6d
    A prospective observational study of Orelabrutinib combined with anti-CD20 monoclonal antibody followed by Orelabrutinib maintenance as first-line treatment for MZ (ChiCTR2500113665)
    P=N/A, N=40, Not yet recruiting, The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib)
    6d
    Rituximab, Lenalidomide, and Orelabrutinib Combination Regimen in the Treatment of marginal zone cell lymphoma: a Prospective, Single-Arm, Phase II Clinical Study (ChiCTR2500115204)
    P2, N=46, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    8d
    topMIND: A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1/2, N=54, Terminated, Incyte Corporation | Completed --> Terminated; A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
    Trial termination • Pan tumor
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Chr t(11;14)
    |
    parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
    8d
    Diagnostic challenges in pediatric lymphomas (PubMed, Pathologie (Heidelb))
    Their diagnosis requires careful consideration to accurately distinguish rare indolent entities, recently defined large B‑cell lymphomas, and reactive mimics. Recent classifications, including the newly introduced WHO Classification of Pediatric Tumors, increasingly reflect these unique aspects.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive
    8d
    Molecular and Cellular Characterization of MALT Lymphoma (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, International Extranodal Lymphoma Study Group (IELSG)
    New trial
    8d
    A case of marginal zone lymphoma presenting with paraneoplastic vasculitis and pulmonary infiltration. (PubMed, Respir Med Case Rep)
    Rituximab monotherapy was initiated, resulting in both clinical and radiological improvement. This case highlights the importance of considering underlying malignancy in patients with unexplained systemic inflammation, vasculitic skin lesions, or cytopenias, particularly when autoimmune markers are negative. Prompt histological diagnosis and multidisciplinary collaboration enabled timely immunochemotherapy, resulting in the resolution of both lymphoma and associated paraneoplastic complications.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab)
    9d
    Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. (clinicaltrials.gov)
    P2, N=23, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib)
    9d
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Valcyte (valganciclovir)